Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun:37:67-78.
doi: 10.1016/j.mib.2017.05.008. Epub 2017 Jun 9.

Diversity, classification and evolution of CRISPR-Cas systems

Eugene V Koonin  1 , Kira S Makarova  2 , Feng Zhang  3
Affiliations
Review

Diversity, classification and evolution of CRISPR-Cas systems

Eugene V Koonin et al. Curr Opin Microbiol. 2017 Jun.

Abstract

The bacterial and archaeal CRISPR-Cas systems of adaptive immunity show remarkable diversity of protein composition, effector complex structure, genome locus architecture and mechanisms of adaptation, pre-CRISPR (cr)RNA processing and interference. The CRISPR-Cas systems belong to two classes, with multi-subunit effector complexes in Class 1 and single-protein effector modules in Class 2. Concerted genomic and experimental efforts on comprehensive characterization of Class 2 CRISPR-Cas systems led to the identification of two new types and several subtypes. The newly characterized type VI systems are the first among the CRISPR-Cas variants to exclusively target RNA. Unexpectedly, in some of the class 2 systems, the effector protein is additionally responsible for the pre-crRNA processing. Comparative analysis of the effector complexes indicates that Class 2 systems evolved from mobile genetic elements on multiple, independent occasions.

PubMed Disclaimer

Conflict of interest statement

Author declaration

We confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author.

Figures

Figure 1
Figure 1. Updated classification of CRISPR-Cas systems
(A) Class 1 (B) Class 2 The organization of the CRISPR-cas loci and domain architectures of the effector proteins as well as the (predicted) target (DNA or RNA, or both) are shown for each subtype. For subtype III-D, a locus with reverse transcriptase fused to cas1 is included; other reverse transcriptase-containing variants, from subtypes III-A and III-D, are not shown. The genes for Class 1 effector subunits are shaded. SS, small subunit; TM, predicted transmembrane segment.
Figure 1
Figure 1. Updated classification of CRISPR-Cas systems
(A) Class 1 (B) Class 2 The organization of the CRISPR-cas loci and domain architectures of the effector proteins as well as the (predicted) target (DNA or RNA, or both) are shown for each subtype. For subtype III-D, a locus with reverse transcriptase fused to cas1 is included; other reverse transcriptase-containing variants, from subtypes III-A and III-D, are not shown. The genes for Class 1 effector subunits are shaded. SS, small subunit; TM, predicted transmembrane segment.
Figure 2
Figure 2. Cryo-electron microscopic structures of type I and type III effector complexes
The Electron Microscopy Data Bank (EMDB) codes are indicated for each structure. The structures are from Refs. [21] (I-C), [20] (I-E), [23] (III-A), [22] (III-B).
Figure 3
Figure 3. The Class 2 effector proteins
(A) Schematic representation of the complexes of effector proteins with the target DNA or RNA, guide RNA and (for type II) tracrRNA (B) Domain architectures of the effector proteins and their transposon-encoded evolutionary ancestors IscB and TnpB are the inferred ancestors of the type II (Cas9) and type V (Cas12) effectors, respectively. The catalytic residues of the effector nuclease domain and, for Cas12a and Cas13a, the residues shown to be required for pre-crRNA processing are indicated in red. The Protein Data Bank (PDB) codes are included for proteins with solved structures. HTH, helix-turn-helix DNA-binding domain. The tracrRNA, the pre-crRNA processing catalytic sites and the nicking, target strand-cleaving nuclease are denoted by asterisks to indicate that they are each present only in subsets of the type II and type V effectors 9see text for details). The catalytic amino acid residues of the target-cleaving nucleases are shown in red, and those of the pre-crRNA processing nuclease are shown in blue. RuvCI, II and III stand for the three conserved motifs of the RuvC-like nuclease domain that contain the catalytic residues. In the motif signature, “x” stands for amino acid, and “..” indicated that the catalytic residues are separated by a small, variable number of non-conserved residues.
See this image and copyright information in PMC

References

    1. Sorek R, Lawrence CM, Wiedenheft B. CRISPR-mediated adaptive immune systems in bacteria and archaea. Annu Rev Biochem. 2013;82:237–266. - PubMed
    1. Wright AV, Nunez JK, Doudna JA. Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering. Cell. 2016;164(1–2):29–44. - PubMed
    1. Komor AC, Badran AH, Liu DR. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. 2016 http://dx.doi.org/10.1016/j.cell.2016.10.044( - DOI - PubMed
    1. Mohanraju P, Makarova KS, Zetsche B, Zhang F, Koonin EV, van der Oost J. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science. 2016;353(6299):aad5147. - PubMed
    1. Pingoud A, Wilson GG, Wende W. Type II restriction endonucleases - a historical perspective and more. Nucleic Acids Res. 2016 - PMC - PubMed